IOVS Health Education Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajala, R. V. S.
Right arrow Articles by Anderson, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajala, R. V. S.
Right arrow Articles by Anderson, R. E.
(Investigative Ophthalmology and Visual Science. 2001;42:3110-3117.)
© 2001 by The Association for Research in Vision and Ophthalmology, Inc.

Interaction of the Insulin Receptor ß-Subunit with Phosphatidylinositol 3-Kinase in Bovine ROS

Raju V. S. Rajala1,2 and Robert E. Anderson1,2,3,4

1 From the Departments of Ophthalmology, 3 Cell Biology, and 4 Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City; and 2 Dean A. McGee Eye Institute, Oklahoma City.


   Abstract
Top
 Abstract
Introduction
 Experimental Procedures
 Results
 Discussion
 References
 
PURPOSE. To identify the tyrosine-phosphorylated protein(s) in bovine rod outer segments (ROS) that are associated with phosphatidylinositol 3-kinase (PI3K).

METHODS. Glutathione-S-transferase (GST) fusion proteins containing two SH2 domains of the p85 regulatory subunit of PI3K—GST-p85 (N-SH2), GST-p85 (C-SH2), and respective SH2 mutants (N-SH2, R358A, and C-SH2, R649A)—were prepared and used to pull down tyrosine-phosphorylated proteins in bovine ROS. Protein identity was established by Western blot analysis. PI3K activity was determined in the pull-down mixtures and in immunoprecipitates by incubation with phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) and [{gamma}32P]adenosine triphosphate (ATP).

RESULTS. The GST pull-down assays indicated the binding of a 97-kDa protein by GST-p85 (N-SH2) in tyrosine-phosphorylated (PY)-ROS that was not present in nonphosphorylated (N)-ROS. Binding was completely abolished when the Arg 358 in the N-SH2 domain was mutated to Ala. Increased binding of the p110{alpha} catalytic subunit to GST-p85 (N-SH2) fusion protein was also observed in the presence of the 97-kDa phosphorylated protein. Biochemical evidence indicated that the 97-kDa protein was the ß-subunit of the insulin receptor ß-subunit (IRß). Immunoprecipitates of PY-ROS and N-ROS with anti-PY antibodies, probed with anti-IRß, indicated the presence of IRß only in PY-ROS. Immunoprecipitates of PY-ROS and N-ROS with anti-IRß antibodies, probed with anti-p85 and anti-p110{alpha} antibodies, indicated increased amounts of both p85 and p110{alpha} in PY-ROS compared to N-ROS. Treatment of ROS with insulin, followed by immunoprecipitation with either anti-IRß or anti-PY, resulted in increased PI3K activity. Expression and phosphorylation of the cytoplasmic tail of retina insulin receptor showed direct involvement with the p85 subunit of PI3K in vitro.

CONCLUSIONS. Tyrosine phosphorylation of the ß-subunit of the insulin receptor is involved in the regulation of PI3K activity in ROS.


   Introduction
Top
 Abstract
 Introduction
Experimental Procedures
 Results
 Discussion
 References
 
Phosphatidylinositol 3-kinase (PI3K) consists of an ~85-kDa regulatory subunit (p85) and a ~110-kDa catalytic subunit (p110), the latter of which is responsible for the phosphorylation of phosphatidylinositol lipids at the D3 position and serine phosphorylation of proteins.1 2 3 The p85 subunit contains a Src homology 3 (SH3) domain capable of binding to proline-rich sequences, a region of homology to the breakpoint cluster region (BCR) gene product, a p110 binding domain, and two SH2 domains (N- and C-terminal). PI3K activity increases in response to receptor activation by the direct binding of the p85 SH2 domain to tyrosine-phosphorylated sites on the receptor.4 5 PI3K activity can also be regulated by activated receptor tyrosine kinase substrates, such as insulin receptor substrate (IRS)-1.6 Ruderman et al.7 first demonstrated the activation of PI3K by insulin, either by stimulating Chinese hamster ovary (CHO) cells with insulin or by transfecting the CHO cells with human insulin receptor. Van Horn et al.8 showed a two-fold activation of PI3K by insulin receptor and also demonstrated the activation of PI3K by tyrosyl phosphopeptide derived from the insulin receptor C terminus in vitro. Thus, there is ample evidence to suggest that the class I p85/p110 complex of PI3K is a common element of numerous signaling pathways involving a large number of tyrosine kinases.9 10 11

Light stimulates tyrosine phosphorylation of several proteins in rat rod outer segments (ROS) in vivo,12 and bovine ROS contain an endogenous tyrosine kinase(s) that can phosphorylate at least 10 proteins in vitro.13 14 The activity of cyclic nucleotide-gated channels from salamander15 and bovine16 ROS could be substantially altered after tyrosine phosphorylation of the {alpha}-subunits of the channel protein. Phospholipase C{gamma}1, the enzyme responsible for hydrolysis of D-myo-phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2) and known to be stimulated by tyrosine phosphorylation,17 18 has been localized in bovine ROS.19 We have reported that bovine retinal ROS contain a class I p85/p110 enzyme complex20 that can be activated in vitro by light and tyrosine phosphorylation of proteins in these membranes.21 In the present study, we identified the mechanism of regulation of PI3K activity in bovine photoreceptor cells through tyrosine phosphorylation of the insulin receptor ß-subunit (IRß).


   Experimental Procedures
Top
 Abstract
 Introduction
 Experimental Procedures
Results
 Discussion
 References
 
Materials
Polyclonal antisera to the p85 regulatory subunit of PI3K, p110{alpha} catalytic subunit of PI3K, mouse monoclonal phosphotyrosine (clone 4G10) antibody, and polyclonal IRß were obtained from Upstate Biotechnology, Inc. (Lake Placid, NY); monoclonal anti-PY99, polyclonal IRß and IRS-1 antibodies from Santa Cruz Biotechnology (Santa Cruz, CA); [{gamma}32P]adenosine triphosphate (ATP) from New England Nuclear (Boston, MA); and anti-glutathione-S-transferase (GST) antibody from Amersham Pharmacia Biotechnology, Inc. (Piscataway, NJ). Echelon Research Laboratories Inc. (Salt Lake City, UT) provided PI-4,5-P2. NIH3T3 cells transfected with the insulin receptor were obtained from Upstate Biotechnology, Inc. Cells harboring elk tyrosine kinase (Epicurian Coli TKX1 competent cells) were obtained from Stratagene (La Jolla, CA). All other reagents were of analytical grade and were from Sigma (St. Louis, MO).

Preparation of ROS
Fresh bovine eyes were obtained from a local abattoir and dissected on ice, and retinas were obtained within 2 hours. ROS were prepared from fresh retinas on a continuous sucrose gradient (25%–50%), as previously described.19 Protein determination was performed with bicinchoninic acid (BCA) reagents (Pierce, Rockford, IL), according to the manufacturer’s instructions.

Preparation of Tyrosine-Phosphorylated ROS
ROS prepared as described have an endogenous tyrosine kinase activity.13 14 Tyrosine-phosphorylated (PY)-ROS were prepared by incubating ROS for 15 minutes at 37°C in a phosphorylation buffer (50 mM Tris-HCl [pH 7.4], 100 mM NaCl, 2 mM MgCl2, 1.5 mM ATP, and 0.2 mM Na3VO3). Nonphosphorylated (N)-ROS were prepared by incubating ROS in a similar buffer without ATP, MgCl2, and NaVO3. After incubation, PY-ROS and N-ROS were solubilized at 4°C for 30 minutes in a solubilization buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, and 10% glycerol).

Immunoprecipitation
PY-ROS and N-ROS were solubilized in a lysis buffer containing 1% Triton X-100, 137 mM NaCl, 20 mM Tris-HCl (pH 8.0), 10% glycerol, 1 mM EGTA, 1 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.2 mM Na3VO4, 10 µg/ml leupeptin, and 1 µg/ml aprotinin. Insoluble material was removed by centrifugation at 17,000g for 20 minutes, and the solubilized ROS were precleared by incubation with 40 µl protein A-Sepharose for 1 hour at 4°C with mixing. The supernatant was incubated with anti-p85 (1:300), anti-p110{alpha} (4 µg), anti-PY (4 µg), or anti-IRß (4 µg) antibodies overnight at 4°C and subsequently with 40 µl protein A-Sepharose for 2 hours at 4°C. Immune complexes were washed twice with modified solubilization buffer (the 1% Triton X-100 was reduced to 0.1% and glycerol was removed) and once with phosphorylation buffer without ATP. Immune complexes were washed twice with modified solubilization buffer (the 1% Triton X-100 was reduced to 0.1% and glycerol was removed) and once with phosphorylation buffer without ATP. Precipitates were assayed for PI3K activity or subjected to immunoblot analysis.

SDS-PAGE and Western Blot Analysis
Protein were resolved by 10% SDS-PAGE and transferred onto nitrocellulose membranes, and the blots were washed two times for 10 minutes with TTBS (20 mM Tris-HCl [pH 7.4], 100 mM NaCl, and 0.1% Tween-20) and blocked with 10% bovine serum albumin in TTBS overnight at 4°C. Blots were then incubated with anti-p85 (1:4000), anti-p110{alpha} (1 µg/ml), anti-IRß (1:1000), anti-PY (1 µg/ml), or anti-GST (1:5000) antibodies for 2 hours at room temperature. After primary antibody incubations, immunoblots were incubated with horseradish peroxidase (HRP)-linked secondary antibodies (anti-rabbit, anti-mouse, or anti-goat IgG) and developed by enhanced chemiluminescence (ECL), according to the manufacturer’s instructions. Quantitative analysis of bands of respective Western blot analysis was performed using NIH Image software, ver. 1.62 (provided in the public domain by the National Institutes of Health, Bethesda, MD, and available at http://rsb.info.nih.gov/nih-image/download.html).

PI3K Assay
Enzyme assays were performed essentially as previously described.22 Briefly, assays were performed directly on immunoprecipitates in 50 µl of the reaction mixture containing 0.2 mg/ml PI-4,5-P2, 50 µM ATP, 0.2 µCi [{gamma}32P]ATP, 5 mM MgCl2, and 10 mM HEPES buffer (pH 7.5). The reactions were performed for 15 minutes at room temperature and stopped by the addition of 100 µl of 1 N HCl followed by 200 µl chloroform-methanol (1:1, vol/vol). Lipids were extracted and resolved on oxalate-coated thin-layer chromatography (TLC) plates (silica gel 60) with a solvent system of 2-propanol/2 M acetic acid (65:35, vol/vol). The plates were coated in 1% (wt/vol) potassium oxalate in 50% methanol (vol/vol) and then baked in an oven at 100°C for 1 hour before use. TLC plates were exposed to x-ray film overnight at -70°C, and radioactive lipids were scraped and quantified by liquid scintillation counting.

GST-p85 Proteins and Pull-Down Experiments
GST-p85 fusion proteins were generated by PCR amplification of the indicated p85 regions and cloned into a vector (pGEX2T; Amersham Pharmacia Biotech). The amino acids of bovine p85{alpha} present in each fusion protein are N-SH2 (314-446) and C-SH2 (614-724), based on the sequence published by Otsu et al.23 The sequence of each clone was verified by DNA sequencing. All inductions yielded proteins of the expected size, as judged by Coomassie blue staining. Pull-down experiments were performed as described,6 using 5 µg GST-fusion proteins that had been adsorbed onto GST-Sepharose 4B matrix. PY-ROS and N-ROS were incubated with GST/GST-p85 fusion proteins with continuous mixing at 4°C for 1.5 hours. The Sepharose beads were washed three times in 500 µl HNTG buffer (20 mM HEPES [pH 7.5], 150 mM NaCl, 0.1% Triton X-100, and 10% glycerol) and centrifuged at 5000 rpm for 30 to 60 seconds at 4°C. GST-p85 fusion proteins and bound proteins were eluted by boiling in 2x SDS sample buffer 5 minutes before 10% SDS-PAGE. After SDS-PAGE, the gels were not stained, but instead were used in a Western blot analysis to visualize the specific protein present. For PI3K activity, the HNTG–washed GST-Sepharose beads were used directly. Blots were stripped and reprobed with anti-GST antibodies to ensure that comparable amounts of GST-p85 fusion proteins were present in each experiment.

Site-Directed Mutagenesis
Site directed mutagenesis was performed by using a quick-change site-directed mutagenesis kit (Stratagene Inc.). The reaction mixture contained SDM buffer (200 mM Tris-HCl [pH 8.8], 100 mM KCl, 100 mM NH4SO4, 20 mM MgSO4, 1% Triton X-100, 1 mg/ml nuclease-free bovine serum albumin), 1 mM deoxynucleotide mix (dATP, dCTP, dTTP, and dGTP), 50 ng GST-pGEX vector containing either p85 (N-SH2) or p85 (C-SH2) fusion proteins, and 125 ng sense and antisense primers with mutations, in a total volume of 50 µl, followed by the addition of 2.5 U pfu DNA polymerase using a programmable thermal controller (PTC 100; MJ Research, Inc., Watertown, MA). The mutant primers were: R358A (sense: ACC TTT TTG GTA GCA GAC GCA TCT ACT AAA; antisense: TTT AGT AGA TGC GTC TGC TAC CAA AAA GGT) and R649A (sense: ACT TTT CTT GTC GCG GAA AGC AGT AAA CAG; antisense: CTG TTT ACT GCT TTC CGC GAC AAG AAA AGT). The extension parameters of SDM were as follows: after denaturation at 95°C for 30 seconds, 16 cycles at 95°C for 30 seconds, 55°C for 1 minute, and at 68°C for 12 minutes (2 min/kb of plasmid length). After temperature cycling, the reaction was placed on ice for 2 minutes, after which 10 U DpnI restriction enzyme was added, mixed, and incubated at 37°C for 60 minutes. Transformation was performed using 1 µl of the DpnI treated reaction to Epicurean XL-blue supercompetent cells, and the reaction was placed on plates coated with Luria-Bertani (LB) agar-ampicillin (100 µl/ml). The cDNAs of all mutants were sequenced after PCR. The only mutations observed were those intentionally introduced to create each desired mutation. The clones were induced with isopropyl ß-D-thiogalactopyranoside (IPTG; 1 mM), and the expressed fusion proteins were purified through GST-Sepharose 4B matrix.

Tyrosine Kinase Assay
A synthetic peptide corresponding in sequence to residues 6-20 of p34cdc2, cdc2 (KVEKIGEGTYGVVKK), was used as a substrate for Src tyrosine kinase.24 The phosphorylation reaction was performed essentially as described by Cheng et al.24 in a total volume of 25 µl of 50 mM Tris-HCl buffer (pH 7.0), 50 mM MgCl2, 5 mM MnCl2, 50 mM Na3VO4, 7 µg/ml p-nitrophenyl phosphate, and protein kinase Src. The reaction was initiated by adding 2.5 µl [{gamma}32P]ATP (2186 counts per minute per picomole) to reach a final concentration of 146 µM, and the reaction was terminated by adding 10 µl 50% (vol/vol) acetic acid. Twenty-five microliters of assay mixture was spotted onto phosphocellulose filter paper discs (1.5 x 1.5 cm), which were immersed in a solution containing 0.75% phosphoric acid (vol/vol), as described.24 The filter paper discs containing the bound phosphorylated peptide were washed three times with phosphoric acid and rinsed in acetone. Radioactivity was quantified in 7.5 ml of a liquid scintillation cocktail and counted (Ready Safe Liquid Scintillation Cocktail and Liquid Scintillation Counter; Beckman, Fullerton, CA).

Cloning of CTIR and Generation of Phosphorylated CTIR
The carboxyl terminal tail of the cytoplasmic tail of insulin receptor (CTIR) was amplified from rat retina cDNA that was reverse transcribed from rat retina total RNA, using rat liver25 insulin receptor–specific primers (sense 5'-GGA TCC TCT CAC TGT CAG AGA GAA GAG GCT; antisense 3'-GAA TTC TTA GGA AGG GTT CGA CCT CGG CGA). All PCR products were sequenced, and the insert was subcloned into the bacterial expression plasmid pGEX-2TK. The PGEX-2TK plasmid was transformed to TKX1-competent cells (Stratagene) that harbor a plasmid-encoded, inducible tyrosine kinase gene, elk tyrosine kinase,26 under the control of the trp promoter. The bacterial cells were grown at 37°C to an optical density at 600 nm (OD600) of approximately 1 and were incubated for 2 hours with 0.1 mM IPTG to induce expression of the GST fusion proteins. The cells were then centrifuged at 2000g, and the pellet was resuspended in TK-induction medium (M9 medium containing indoleacrylic acid) for 2 hours, according to the manufacturer’s instructions. The cells were collected and frozen at -80°C until used. Frozen cell pellets were sonicated in ice-cold PASE lysis buffer (50 mM HEPES, [pH 7.5], 50 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 10 µg/ml aprotinin, 10 µg/ml leupeptin, and 1 mM PMSF) and clarified by centrifugation. The supernatants were incubated with GST-Sepharose 4B matrix for 30 minutes at 4°C. The beads were then washed several times with ice-cold PBS, and the pellets were resuspended in PASE lysis buffer and used for in vitro binding after examining the phosphorylation on the insulin receptor kinase tail, using phosphotyrosine antibodies. In vitro binding assays were performed by using the nonphosphorylated and phosphorylated CTIR domain by incubating the beads with solubilized N-ROS for 90 minutes followed by GST pull-down assays. The GST beads were used for Western blot analysis with the anti-p85{alpha} regulatory subunit of PI3K and measured the PI3K activity, using PI-4–5-P2 as substrate.


   Results
Top
 Abstract
 Introduction
 Experimental Procedures
 Results
Discussion
 References
 
Effect of Tyrosine Phosphorylation on PI3K Activity in ROS
The effect of tyrosine phosphorylation on PI3K activity was determined in immunoprecipitates of PY-ROS and N-ROS, using PI-4,5-P2 as a substrate. PI3K activity was approximately two times higher in anti-p85 IPs from PY-ROS than in N-ROS (Figs. 1A 1D) . p110{alpha} IPs from PY-ROS also had higher PI3K activity (~1.5-fold) than those from N-ROS (Figs. 1B 1D) . The strongest effect was found in anti-PY IPs, where PY-ROS had approximately 10 times the PI3K activity as N-ROS (Figs. 1C 1D) . The relative amount of p85 in the IPs was determined by densitometric scans of Western blot probed with an anti-p85 antibody, and the density values are shown below the top panels. Anti-p85 and anti-p110 IPs from PY-ROS and N-ROS contained a similar amount of p85, whereas the amount of p85 in anti-PY IPs was approximately 10 times higher in PY-ROS.



View larger version (50K):
[in this window]
[in a new window]
  		Figure 1. TLC autoradiograms of PI3K activity in (A) anti-p85, (B) anti-p110{alpha}, and (C) anti-PY IPs from 500 µg PY-ROS (lane P) or N-ROS (lane N), using PI-4,5-P2 and [{gamma}32P]ATP as substrates (bottom). For Western blot analysis (top), equal amounts of PY-ROS and N-ROS (300 µg) were solubilized and immunoprecipitated (A) anti-p85, (B) p110{alpha}, or (C) anti-PY antibodies and were probed with anti-p85 antibody. Values under each blot (top) are the relative density of p85 determined by scanning densitometry. (D) Relative levels of PI3K activity in anti-p85, anti-p110{alpha}, and anti-PY IPs. The level of PI3K in N-ROS was set as 1.0 for comparison. Data are mean ± SD for four independent ROS preparations.

 
p85 Protein Associated with Anti-PY IPs
Anti-PY IPs from PY-ROS and N-ROS were subjected to Western blot analysis with an anti-p85 antibody to determine whether the higher PI3K activity observed in anti-PY IPs from PY-ROS is due to increased amounts of p85. The p85-immunoreactive band was seen only in anti-PY IPs from PY-ROS (Fig. 1C , top). However, tyrosine phosphorylation of p85 was not observed on Western blot analysis of either anti-p85 or anti-p110{alpha} IPs from PY-ROS and N-ROS probed with anti-PY (data not shown). These results indicate that a tyrosine-phosphorylated protein in bovine ROS could be binding to the SH2 domain(s) of the p85 regulatory subunit, and this protein may be involved in the activation of PI3K activity. This speculation is consistent with our results showing that the anti-PY IP pulled down the p85 in response to ROS phosphorylation.

Identification of the 97-kDa Protein from GST-p85 Pull-Down Experiments
PY-ROS and N-ROS were incubated with GST and respective p85 wild-type and mutated fusion proteins in a GST pull-down assay. After incubation, the fusion proteins were resolved by SDS-PAGE and transferred to nitrocellulose, and the resultant Western blots were probed with anti-PY antibody. We identified a 97-kDa immunoreactive band only in the GST-p85 (N-SH2) domain on Western blot analysis (Fig. 2A) . No binding was observed in GST-p85 (N-SH2, R358A) mutant fusion protein (lane 4), demonstrating the specificity of the phosphorylation-dependent binding. When the blot was stripped and reprobed with anti-p110{alpha} antibody (Fig. 2B) , an increased amount of p110{alpha} immunoreactivity was observed in the GST-p85 (N-SH2) domain. PI3K activity was also higher in the GST-p85 (N-SH2) fusion protein samples (data not shown). These results suggest that the increased PI3K activity in anti-PY IPs is due to the increased amount of p110{alpha} bound to the 97-kDa tyrosine-phosphorylated protein.



View larger version (30K):
[in this window]
[in a new window]
  		Figure 2. GST pull-down experiments. PY-ROS and N-ROS (175 µg each) were incubated with (lane 1) GST, (lane 2) GST-p85 (N-SH2), (lane 3) GST-p85 (C-SH2), (lane 4) GST-p85 (N-SH2, R358A), or (lane 5) GST-p85 (C-SH2, R649A) fusion proteins, followed by Western blot analysis of the bound proteins with anti-PY antibody (A). The blot was stripped and reprobed with anti-p110{alpha} antibody (B).

 
Characterization of the 97-kDa Tyrosine-Phosphorylated Protein
To test the possibility that the identified tyrosine-phosphorylated protein could be a member of the Src tyrosine kinase family or a higher molecular weight isoform, we eluted the bound tyrosine-phosphorylated protein with phenyl phosphate and performed a tyrosine kinase assay using the 97-kDa protein as substrate, using c-Src as the protein kinase. To determine whether the 97-kDa protein could be a member of the Src tyrosine kinase family, we used the 97-kDa protein as the source of protein kinase and incubated it with cdc2 peptide as substrate. The results show that the 97-kDa protein does not phosphorylate the peptide substrate, under conditions in which both are phosphorylated by cSrc (Table 1) . This experiment ruled out the possibility that the 97-kDa protein is a nonreceptor tyrosine kinase family member.


View this table:
[in this window]
[in a new window]
  		Table 1. Phosphorylation of 97-kDa Protein by cSrc

 
Identification of the 97-kDa Protein as the IRß
The apparent molecular weight of the phosphorylated protein bound by the GST-p85 (N-SH2) fusion protein was similar to that of the ß-subunit of the insulin receptor.27 To test this possibility, ROS was probed with an antibody to IRß and indicated an abundant presence of IRß in these membranes (Fig. 3A) . NIH3T3 cells transfected with the insulin receptor were used as a positive control. The molecular weight of NIH3T3 cell IRß subunit is slightly higher than IRß from ROS, possibly because of the extent of glycosylation that could alter the mobility of the protein.



View larger version (59K):
[in this window]
[in a new window]
  		Figure 3. Identification of the 97-kDa protein as the IRß-subunit. (A) Twenty micrograms ROS was subjected to immunoblot with anti-IRß. Protein from NIH3T3 cells transfected with the insulin receptor served as a positive control. (B) GST pull-down assays were performed on PY-ROS and N-ROS incubated with GST and GST-p85 (N-SH2) fusion proteins. These fusion proteins were washed and subjected to Western blot analysis with an anti-IRß antibody. (C) The blot was then stripped and probed with anti-GST antibody.

 
To determine whether the 97-kDa protein identified as IRß is involved in PI3K binding, we incubated the GST and GST-p85 (N-SH2) fusion proteins with PY-ROS or N-ROS and subjected each to GST pull-down assays. After incubation, the fusion proteins were resolved by SDS-PAGE and the resultant Western blots were probed with anti-IRß antibody. An immunoreactive band of IRß was observed only in PY-ROS that were pulled down with the GST-p85 (N-SH2) domain (Fig. 3B) . The blot was then stripped and reprobed with an anti-GST antibody to demonstrate that equal amounts of GST were present in each sample (Fig. 3C) .

The other approach we used to identify IRß was to elute the material from the GST-binding experiment described earlier with phenyl phosphate and electrophorese it on a 10% SDS-PAGE 0.7-mm-thick gel and stain with Coomassie blue. Once the band was visualized on the gel, it was cut with a clean razor blade and placed onto another 10% SDS-PAGE 1.0-mm-thick gel, to facilitate the placement of the 0.75-mm-thick slice of the first gel. The gel was run at 100 V and transferred to nitrocellulose, and the resultant Western blot was probed with the anti-IRß antibody. The results show an immunoreactive band of IRß (Fig. 4) , further confirming the identity of the 97-kDa protein as IRß.



View larger version (28K):
[in this window]
[in a new window]
  		Figure 4. Identification of the 97-kDa protein as IRß. (A) NIH3T3 cells transfected with the insulin receptor served as a positive control. (B) Protein eluted with phenyl phosphate was subjected to 10% SDS-PAGE with 0.75-mm-thick gels stained with Coomassie blue. The band was visualized, excised, and placed on a second 10% SDS-PAGE 1.0-mm-thick gel. The gel was transferred to nitrocellulose and probed with anti-IRß antibody.

 
To examine the association between IRß and the p85-p110 complex, we immunoprecipitated IRß from PY-ROS and N-ROS and probed the ensuing Western blots with anti-IRß, anti-p85, or anti-P110{alpha}. The presence of IRß was also examined in PY-ROS and N-ROS immunoprecipitated with an anti-PY antibody. The results indicate no difference in the amount of IRß in either PY-ROS or N-ROS (Fig. 5A) , when immunoprecipitated with the anti-IRß antibody, which was the expected result. IPs of PY-ROS and N-ROS, using the anti-PY antibody, probed with anti-IRß antibody, indicated the presence of IRß only in PY-ROS (Fig. 5B) , suggesting that tyrosine-phosphorylated IRß can be pulled down by the anti-PY antibody. When Western blots of anti-IRß IPs were probed with anti-p85 or anti-P110{alpha} antibodies, there were increased amounts of each (Figs. 5C 5D) in PY-ROS compared with N-ROS. IPs of PY-ROS and N-ROS with anti-IRß probed with anti-PY antibody showed tyrosine phosphorylation of IRß only in PY-ROS (Fig. 5E) . The weaker signal with anti-PY compared with anti-p110 and -p85 antibodies in the PY-ROS could be due to differences in the relative strength of the antibodies. As can be seen from the blot, there was no apparent immunoreactivity with the anti-PY antibody in N-ROS, although we saw anti-p110 and -p85 immunoreactivity in N-ROS. It is known that basal phosphorylation is associated with the insulin receptor. Thus, the anti-PY antibodies may not detect the low signal, which could be detected by the anti-p110 and -p85 antibodies. These results suggest that tyrosine phosphorylation of IRß is essential for interaction with the p85–110{alpha} complex of PI3K through the N-SH2 domain of p85.



View larger version (54K):
[in this window]
[in a new window]
  		Figure 5. Immunoblots of ROS immunoprecipitated with anti-IRß or anti-PY antibodies. PY-ROS and N-ROS (500 µg each) were subjected to immunoprecipitation with anti-IRß and probed with (A) anti-IRß, (C) anti-p110{alpha}, (D) anti-p85, or (E) anti-PY antibodies. PY-ROS and N-ROS (500 µg) were subjected to immunoprecipitation with anti-PY antibody and probed with (B) anti-IRß antibody.

 
Effect of Insulin on PI3K Activity
To test the effect of insulin on PI3K activity, N-ROS were either phosphorylated or treated with insulin and immunoprecipitated with anti-IRß, and the IPs were assayed for PI3K activity with PI-4,5-P2 as a substrate. Increased PI3K activity was associated with the ROS treated either with ATP (Fig. 6 , lane 1) or insulin (Fig. 6 , lane 3) compared with untreated ROS (lanes 2, 4, 6). Furthermore, N-ROS incubated with insulin followed by immunoprecipitation with anti-PY antibody had significantly higher PI3K activity than nontreated N-ROS (Fig. 6 , lane 5). Western blot analysis of the anti-PY IPs of ROS probed with the anti-IRß antibody showed increased immunoreactivity in the insulin-treated samples (data not shown). These results suggest that phosphorylation and insulin treatment have the same effect—that is, the phosphorylation of IRß.



View larger version (78K):
[in this window]
[in a new window]
  		Figure 6. TLC autoradiograms demonstrating the effects of phosphorylation and insulin on PI3K activity. ROS (500 µg) were either phosphorylated (lane 1), nonphosphorylated (lane 2), or treated with (lane 3) or without (lane 4) 1 µM insulin, and subjected to immunoprecipitation with anti-IRß antibody. PI3K activity associated with anti-IRß immunoprecipitates was measured using PI-4,5-P2 and [{gamma}32P]ATP as substrates. N-ROS (500 µg) were either incubated with (lane 5) or without (lane 6) 1 µM insulin and immunoprecipitated with anti-PY antibody and measured for PI3K activity.

 
Direct Interaction of the p85 Subunit of PI3K with the Phosphorylated CTIR
The rat CTIR was cloned by RT-PCR, using rat liver cDNA primers (Fig. 7A) and coexpressed in Escherichia coli with an inducible tyrosine kinase. After induction of elk expression, the GST-CTIR fusion protein became phosphorylated on tyrosine, as detected by Western blot analysis of isolated GST-fusion proteins with anti-PY antibodies (Fig. 7B) . The parental GST protein was not phosphorylated when coexpressed with elk tyrosine kinase (Fig. 7B) . The GST fusion proteins in their nonphosphorylated or tyrosine-phosphorylated forms were immobilized on glutathione-agarose beads and incubated with solubilized N-ROS, followed by GST pull-down assays. There was increased p85 binding (Fig. 7C) and PI3K activity (Fig. 7E) to phosphorylated GST-CTIR, compared with nonphosphorylated GST-CTIR. When the p85 blots were stripped and reprobed with anti-IRS-1 antibody, no binding of IRS-1 was found, either to phosphorylated or nonphosphorylated CTIR (data not shown), showing the direct interaction of p85 with phosphorylated CTIR independent of IRS-1. The blot was then stripped and reprobed with an anti-GST antibody to demonstrate that equal amounts of GST were present in each sample (Fig. 7D) .



View larger version (48K):
[in this window]
[in a new window]
  		Figure 7. Effect of phosphorylation of the insulin receptor on PI3K activity. (A) CTIR was cloned from rat retina by RT-PCR. The YTHM motif is underlined. To determine coexpression of GST/GST-CTIR, with or without elk tyrosine kinase, the expressed proteins were immunoblotted with anti-PY (B), incubated with NP-ROS (200 µg) followed by GST pull-down assays and immunoblotted with anti-p85 (C). PI3K activity associated with either nonphosphorylated or phosphorylated CTIR were measured using PI-4,5-P2 as substrate (E). The blot was stripped and probed with anti-GST antibody (D).

 

   Discussion
Top
 Abstract
 Introduction
 Experimental Procedures
 Results
 Discussion
References
 
The involvement of protein tyrosine phosphorylation in the regulation of PI3K activity is well documented.22 28 29 30 31 In response to various stimuli, such as platelet-derived growth factor (PDGF)32 and insulin,33 tyrosine phosphorylation of p85 has been shown to occur in several cell types. In most cases, however, PI3K is regulated through the receptor and nonreceptor tyrosine kinases without apparent phosphorylation of the p85 subunit.10 34 35 To understand whether tyrosine phosphorylation is involved in the activation of PI3K in ROS, in vitro conditions that favor tyrosine phosphorylation were used.13 14 We observed that PI3K activity from p85 and P110{alpha} IPs was 1.5 to 2 times greater in PY-ROS than in N-ROS (Fig. 1) , in agreement with our previous work.21 The increase of PI3K activity in anti-p85 and anti-p110{alpha} IPs from PY-ROS could be due to a greater amount of enzyme in the IP, activation of the enzyme by phosphorylation, or activation by some other mechanism. To investigate these possibilities, anti-p85 and anti-p110{alpha} IPs from PY-ROS and N-ROS were subjected to Western blot analysis, with anti-p85 or anti-p110{alpha} antibodies as probes. The amount of p85 and p110{alpha} in the IPs was not different between PY-ROS and N-ROS. Blots probed with anti-PY antibody showed that neither p85 nor p110{alpha} was phosphorylated, suggesting that the twofold increase in enzyme activity is probably due to the influence of some tyrosine-phosphorylated protein in the IPs.

Because the phosphorylation conditions used in this study are designed to promote tyrosine phosphorylation, anti-PY IPs from PY-ROS and N-ROS were obtained and assayed for PI3K activity and p85 protein expression. PI3K activity in anti-PY IPs from PY-ROS was 10 times that from N-ROS, and Western blot analysis probed with the anti-p85 antibody showed that the amount of p85 in IPs from PY-ROS was also approximately 10 times that in the IPs from N-ROS. These results indicate that the p85 regulatory subunit is most likely bound to and coimmunoprecipitates with a tyrosine-phosphorylated protein, in response to phosphorylation of ROS.

Src homology 2 (SH2) domains are found in a variety of cytoplasmic proteins involved in mediating signals from cell surface receptors to various intracellular pathways.36 They fold as molecular units and are capable of recognizing and binding to proteins and linear peptide sequences containing phosphorylated tyrosine residues.37 To identify and characterize the tyrosine-phosphorylated protein(s) in ROS, we constructed two GST-p85 (SH2) mutant fusion protein (N- and C-SH2 domains). GST pull-down assays on PY-ROS and N-ROS followed by Western blot analysis using an anti-PY antibody indicated the binding of a 97-kDa tyrosine-phosphorylated protein to GST-p85 (N-SH2) fusion protein. No binding was observed in GST-p85 (N-SH2, R358A) mutant fusion protein, suggesting the specificity of phosphorylation-dependent binding. Van Horn et al.8 reported a similar finding, although they also saw a low level of binding to the C-terminus of their GST-p85 fusion protein. We found increased binding of p110{alpha} and an increase in PI3K activity in the presence of the 97-kDa protein bound to the GST-p85 (N-SH2) domain, which suggests that a p85-p110{alpha}-97-kDa protein complex is sufficient to explain the increased PI3K activity in anti-PY IPs. However, the involvement of other proteins could not be ruled out by these experiments.

Several studies have shown that the ß-subunit of the insulin receptor and the insulin-like growth factor (IGF)-1 receptor can be phosphorylated in whole retina and ROS in response to insulin27 38 and IGF-1.39 40 Using immunocytochemistry techniques, Rodrigues et al.41 found the insulin receptor to be localized in photoreceptor and neuronal cell bodies, with lower immunoreactivity in ROS. Bell et al.13 14 reported a 97-kDa protein in ROS that was actively phosphorylated in vitro under conditions that favor tyrosine phosphorylation, and Ghalayini et al.12 showed that a 97-kDa protein is phosphorylated in rat ROS in a light-dependent manner in vivo. Based on these studies, we suspected that the 97-kDa protein we found bound to the p85 regulatory subunit of PI3K could be the IRß subunit, and the experiments described herein show that this is indeed the case.

Although it is known that PI3K can be activated in other tissues by insulin,7 there is no evidence that the insulin receptors in the retina undergo any physiological response after insulin stimulation. In our study, we observed a basal level of insulin receptor phosphorylation in N-ROS accompanied by low PI3K activity (Fig. 6 , lanes 2, 4, 6). Under conditions favorable for phosphorylation, we observed an increase in the PI3K activity that could be due to the increased phosphorylation of insulin receptor (Fig. 6 , lane 1). This phenomenon is also true when the ROS were treated in the presence of insulin, followed by immunoprecipitation with anti-IRß, which resulted in increased PI3K activity (Fig. 6 , lane 3). Increased PI3K activity was also observed from the IPs of PY from insulin-treated ROS (Fig. 6 , lane 5), further confirming that insulin-induced, tyrosine phosphorylation-autophosphorylation of IRß leads to the increased PI3K activity.

The regulatory p85 subunit of PI3K binds to phosphotyrosine at a YXXM motif42 in IRS-1 and thereby activates the catalytic p110 subunit.43 It is surprising that inactivation of the IRS-1 gene in the mouse, by the homologous recombination approach, did not result in any dramatic pathologic phenotype, suggesting the possible existence of alternative signaling pathways.44 45 It has also been shown that wild-type insulin receptor binds tightly to the SH2 domains of p85, whereas the mutant insulin receptor truncated by 43 amino acids at the C terminus binds poorly to the SH2 domains that do not have the Y1322THM motif.8 To examine the binding properties of the noncatalytic regions of the insulin receptor containing the YTHM motif, this sequence was expressed in bacteria and inducibly phosphorylated on tyrosine, thereby mimicking receptor autophosphorylation normally induced by ligand binding. The phosphorylated C-terminal tail of the insulin receptor bound to the p85 subunit of PI3K in N-ROS, and the resultant complex contained PI3K activity. These results are consistent with the notion that noncatalytic cytoplasmic regions of growth factor receptors provide phosphorylation-dependent binding sites for SH2-containing signaling proteins. Furthermore, because there was no binding of IRS-1 to the phosphorylated C-terminal tail of the insulin receptor, the evidence supports a direct interaction of p85 subunit of PI3K with the CTIR, independent of IRS-1.

Our experiments on PI3K activation through its interaction with the 97-kDa protein identified as IRß could not rule out the possibility of the involvement of the IGF-1 receptor ß-subunit, which also has an apparent molecular weight of 97 kDa.38 Indeed, both insulin and IGF-1 can stimulate PI3K in bovine lens.46 Our phosphorylation and binding experiments could have included IGF-1ß, which would not have been detected by the anti-IRß antibody. Similarly, the experiments using immunoprecipitation with the anti-PY antibody could not differentiate between the ß-subunits of insulin and IGF-1 receptors. However, the antibody we used against IRß does not cross-react with IGF-1ß (catalog no. SC-711; Santa Cruz Biotechnology), and immunoprecipitation with anti-IRß followed by Western blot analysis with the anti-p85 antibody or measuring the PI3K activity clearly showed an association between IRß and PI3K. Also, the phosphorylated GST-CTIR fusion protein that bound the p85 subunit of PI3K contained the insulin sequence, which is different from the IGF-1 sequence. Therefore, we feel confident in concluding that phosphorylation of the ß-subunit of the insulin receptor in ROS leads to its association with PI3K. Studies are currently under way to determine whether PI3K also associates with IGF-1 receptors in photoreceptor cells.

In vitro20 21 and in vivo47 studies in our laboratory have now shown that the activity of PI3K in the retina can be controlled by light and tyrosine phosphorylation. We speculate that the molecular mechanism of the activation is through binding of the p85 regulatory subunit of PI3K to the ß-subunit of the insulin receptor. The role of PI3K in photoreceptor outer segments is not known. However, its function could be related to the activities driven by light, such as shedding of photoreceptor tips, biogenesis of new ROS membranes through addition of newly synthesized membranes at the base of the ROS, or light adaptation. Also, environmental and genetic (mutation) stresses lead to death of rod and cone photoreceptor cells. In some neuronal cell types, such as cerebellar granular neurons48 and PC-12 cells,49 receptor activation of PI3K has been shown to protect these cells from stress-induced neurodegeneration. Whether PI3K activation protects the retina from stress is currently under study in our laboratory.


   Footnotes
 
Supported by Grants EY00871, EY04149, and EY12190 from the National Eye Institute; Research to Prevent Blindness; The Foundation Fighting Blindness; the Samuel Roberts Nobel Foundation, Inc., Ardmore, Oklahoma; and the Presbyterian Health Foundation, Oklahoma City.

Submitted for publication May 29, 2001; revised August 9, 2001; accepted August 16, 2001.

Commercial relationships policy: N.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Raju V. S. Rajala, 608 Stanton L. Young Boulevard, Room 409, Oklahoma City, OK 73104. raju-rajala{at}ouhsc.edu


   References
Top
 Abstract
 Introduction
 Experimental Procedures
 Results
 Discussion
 References
 

  1. Carpenter, CL, Duckworth, BC, Auger, KR, Cohen, B, Schaffhausen, BS, Cantley, LC (1990) Purification and characterization of phosphoinositide 3-kinase from rat liver J Biol Chem 265,19704-19711[Abstract/Free Full Text]
  2. Dhand, R, Hiles, I, Panayotou, G, et al (1994) PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity EMBO J 13,522-533[Medline][Order article via Infotrieve]
  3. Skolnik, EY, Margolis, B, Mohammadi, M, et al (1991) Cloning of PI3K-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases Cell 65,83-90[Medline][Order article via Infotrieve]
  4. Hu, P, Mondino, A, Skolnik, EY, Schlessinger, J. (1993) Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85 Mol Cell Biol 13,7677-7688[Abstract/Free Full Text]
  5. Klippel, A, Escobedo, JA, Fantl, WJ, Williams, LT (1992) The C-terminal SH2 domain of p85 accounts for the high affinity and specificity of the binding of phosphatidylinositol 3-kinase to phosphorylated platelet-derived growth factor beta receptor Mol Cell Biol 12,1451-1459[Abstract/Free Full Text]
  6. McGlade, CJ, Ellis, C, Reedijk, M, et al (1992) SH2 domains of the p85{alpha} subunit of phosphatidylinositol 3-kinase regulate binding to growth factor receptors Mol Cell Biol 12,991-997[Abstract/Free Full Text]
  7. Ruderman, NB, Kapeller, R, White, MF, Cantley, LC (1990) Activation of phosphatidylinositol 3-kinase by insulin Proc Natl Acad Sci USA 87,1411-1415[Abstract/Free Full Text]
  8. Van Horn, DJ, Myers, MG, Jr, Backer, JM (1994) Direct activation of the phosphatidylinositol 3-kinase by the insulin receptor J Biol Chem 269,29-32[Abstract/Free Full Text]
  9. Fruman, DA, Meyers, RE, Cantley, LC (1998) Phosphoinositide kinases Annu Rev Biochem 67,481-507[Medline][Order article via Infotrieve]
  10. Fry, MT (1994) Structure, regulation and function of phosphatidylinositol 3-kinase Biochim Biophys Acta 1226,237-268[Medline][Order article via Infotrieve]
  11. Martin, TFJ (1998) Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation and membrane trafficking Annu Rev Cell Dev Biol 14,231-264[Medline][Order article via Infotrieve]
  12. Ghalayini, AJ, Guo, XX, Koutz, CA, Anderson, RE (1998) Light stimulates tyrosine phosphorylation of rat rod outer segments in vivo Exp Eye Res 66,817-821[Medline][Order article via Infotrieve]
  13. Bell, MW, Alvarez, K, Ghalayini, AJ (1999) Association of tyrosine phosphatase SHP-2 with transducin-{alpha} and a 97 kDa tyrosine phosphorylated protein in photoreceptor rod outer segments J Neurochem 73,2331-2340[Medline][Order article via Infotrieve]
  14. Bell, MW, Desai, N, Guo, XX, Ghalayini, AJ (2000) Tyrosine phosphorylation of the alpha subunit of transducin and its association with src in photoreceptor rod outer segments J Neurochem 75,2006-2019[Medline][Order article via Infotrieve]
  15. Molokanova, E, Trivedi, B, Savchenko, A, Kramer, RH (1997) Modulation of rod photoreceptor cyclic nucleotide-gated channels by tyrosine phosphorylation J Neurosci 17,9068-9076[Abstract/Free Full Text]
  16. Molokanova, E, Maddox, F, Luetje, CW, Kramer, RH (1999) Activity-dependent modulation of rod photoreceptor cyclic nucleotide-gated channels mediated by phosphorylation of a specific tyrosine residue J Neurosci 19,4786-4795[Abstract/Free Full Text]
  17. Rhee, SG, Bae, YS (1997) Regulation of phosphoinositide-specific phospholipase C isozymes J Biol Chem 272,15045-15048[Free Full Text]
  18. Schlessinger, J. (1997) Phospholipase Cgamma activation and phosphoinositide hydrolysis are essential for embryonal development Proc Natl Acad Sci USA 94,2798-2799[Free Full Text]
  19. Ghalayini, AJ, Weber, NR, Rundle, DR, et al (1998) Phospholipase Cgama1 in bovine rod outer segments: immunolocalization and light-dependent binding to membranes J Neurochem 70,171-178[Medline][Order article via Infotrieve]
  20. Guo, XX, Ghalayini, AJ, Chen, HM, Anderson, RE (1997) Phosphatidylinositol 3-kinase in bovine photoreceptor rod outer segments Invest Ophthalmol Vis Sci 38,1873-1882[Abstract/Free Full Text]
  21. Guo XX, ,, Huang Z, ,, Bell MW, ,, Chen H, ,, Anderson RE. , (2000) Tyrosine phosphorylation is involved in phosphatidylinositol 3-kinase activation in bovine rod outer segments Mol Vis 6,216-221available at http//:www.molvis.org/molvis/v6/p216/[Medline][Order article via Infotrieve]
  22. Kaplan, DR, Whitman, M, Schaffhausen, B, et al (1987) Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity Cell 50,1021-1029[Medline][Order article via Infotrieve]
  23. Otsu, M, Hiles, I, Gout, I, et al (1991) Characterization of two 85 kd protein that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI 3-kinase Cell 65,91-104[Medline][Order article via Infotrieve]
  24. Cheng, HC, Litwin, CM, Hwang, DM, Wang, JH (1991) Structural basis of specific and efficient phosphorylation of peptides derived from p34cdc2 by pp60src-related protein tyrosine kinase J Biol Chem 266,17919-17925[Abstract/Free Full Text]
  25. Goldstein, BJ, Dudley, AL (1990) The rat insulin receptor: primary structure and conservation of tissue-specific alternative messenger RNA splicing Mol Endocrinol 4,235-244[Abstract]
  26. Lhotak, V, Greer, P, Letwein, K, Pawson, T (1991) Characterization of elk, a brain-specific receptor tyrosine kinase Mol Cell Biol 11,2496-2502[Abstract/Free Full Text]
  27. Waldbilling, RJ, Fletcher, RT, Chader, GJ, Rajagopalan, S, Rodrigues, M, LeRoith, D. (1987) Retinal insulin receptors. 1: structure heterogeneity and functional characters Exp Eye Res 45,823-835[Medline][Order article via Infotrieve]
  28. Kanagasundaram, V, Jaworowski, A, Hamilton, JA (1996) Association between phosphatidylinositol 3-kinase, Cbl and other tyrosine phosphorylated proteins by colony stimulating factor-stimulated macrophages Biochem J 320,69-77
  29. Pleiman, CM, Hertz, WM, Cambier, JC (1994) Activation of phosphatidylinositol 3-kinase by Src-family kinase SH3 binding to the p85 subunit Science 263,1609-1612[Abstract/Free Full Text]
  30. Soltoff, SP, Rabin, SL, Cantley, LC, Kaplan, DR (1992) Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with trk tyrosine kinase J Biol Chem 267,17472-17477[Abstract/Free Full Text]
  31. Thomas, JW, Ellis, B, Boerner, RJ, Knight, WB, White, GC, II, Schaller, MD (1998) SH2-and SH3 mediated interactions between focal adhesion kinase and Src J Biol Chem 273,577-583[Abstract/Free Full Text]
  32. Kavanaugh, WM, Klippel, A, Escobedo, JA, Williams, LT (1992) Modification of the 85-kilodalton subunit of phosphatidylinositol 3-kinase in platelet-derived growth factor-stimulated cells Mol Cell Biol 12,3415-3424[Abstract/Free Full Text]
  33. Hayashi, H, Miyake, N, Kanai, F, Shibasaki, F, Takenawa, T, Ebina, Y. (1991) Phosphorylation in vitro of the 85 kDa subunit phosphatidylinositol 3-kinase and its possible activation by insulin receptor tyrosine kinase Biochem J 280,769-775
  34. Gesbert, F, Garbay, C, Bertoglio, J. (1988) Interleukin-2 stimulation induces tyrosine phosphorylation of p120Cbl and CrkL and formation of multimolecular signaling complex in T lymphocytes and natural killer cells J Biol Chem 273,3986-3993[Abstract/Free Full Text]
  35. Hiles, ID, Otsu, M, Volinia, S, et al (1992) Phosphatidylinositol 3-kinase: structure, expression of the p110 kd catalytic subunit Cell 70,419-429[Medline][Order article via Infotrieve]
  36. Moran, MF, Koch, CA, Anderson, D, et al (1990) Src homology region 2 domains direct protein-protein interactions in signal transduction Proc Natl Acad Sci USA 87,8622-8626[Abstract/Free Full Text]
  37. Waksman, G, Shoelson, SE, Pant, N, Cowburn, D, Kuriyan, J. (1993) Binding of high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free form Cell 72,779-790[Medline][Order article via Infotrieve]
  38. Waldbilling, RJ, Fletcher, RT, Chader, GJ, Rajagopalan, S, Rodrigues, M, LeRoith, D. (1987) Retinal insulin receptors. 2: characterization and insulin-induced tyrosine kinase activity in bovine retinal rod outer segments Exp Eye Res 45,837-844[Medline][Order article via Infotrieve]
  39. Waldbilling, RJ, Fletcher, RT, Somers, RL, Chader, GJ (1988) IGF-1 receptors in the bovine neural retina: structure, kinase activity and comparison with retinal insulin receptors Exp Eye Res 47,587-607[Medline][Order article via Infotrieve]
  40. Zick, Y, Spiegel, AM, Sagi-Eisenberg, R. (1987) Insulin like growth factor I receptor in retinal rod outer segments J Biol Chem 262,10259-10264[Abstract/Free Full Text]
  41. Rodrigues, M, Waldbilling, RJ, Rajagopalan, S, Hackett, J, LeRoith, D, Chader, GJ (1988) Retinal insulin receptors: localization using a polyclonal anti-insulin receptor antibody Brain Res 443,389-394[Medline][Order article via Infotrieve]
  42. Songyang, Z, Shoelson, SE, Chaudhuri, M, et al (1993) SH2 domains recognize specific phosphopeptide sequences Cell 72,767-778[Medline][Order article via Infotrieve]
  43. White, MF, Khan, CR (1994) The insulin signaling system J Biol Chem 269,1-4[Free Full Text]
  44. Araki, E, Lipes, MA, Patti, ME, et al (1994) Alternative pathways of insulin signaling in mice with targeted disruption of the IRS-1 gene Nature 372,186-190[Medline][Order article via Infotrieve]
  45. Tamemoto, H, Kadowaki, T, Tobe, K, et al (1994) Insulin resistance and growth retardation in mice lacking insulin receptor substrate Nature 372,182-186[Medline][Order article via Infotrieve]
  46. Chandrasekher, G, Bazan, HE (2000) Phosphatidylinositol 3-kinase in bovine lens and its stimulation by insulin and IGF-1 Invest Ophthalmol Vis Sci 41,844-849[Abstract/Free Full Text]
  47. Rajala, RVS, Anderson, RE (2001) Light induced activation of phosphatidylinositol 3-kinase in rat retina [ARVO Abstract] Invest Ophthalmol Vis Sci 42(4),S192Abstract nr 1033
  48. D’Mello, SR, Borodezt, K, Soltoff, SP (1997) Insulin like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: possible involvement of PI 3-kinase in IGF-1 signaling J Neurosci 17,1548-1560[Abstract/Free Full Text]
  49. Spear, N, Estevez, AG, Barbeito, L, Beckman, JS, Johnson, GV (1997) Nerve growth factor protects PC12 cells against peroxynitrite-induced apoptosis via a mechanism dependent on phosphatidylinositol 3-kianse J Neurochem 69,53-59[Medline][Order article via Infotrieve]



This article has been cited by other articles:


Home page
 IOVSHome page
S. K. Biswas, Y. Zhao, A. Nagalingam, T. W. Gardner, and L. Sandirasegarane
PDGF- and Insulin/IGF-1-Specific Distinct Modes of Class IA PI 3-Kinase Activation in Normal Rat Retinas and RGC-5 Retinal Ganglion Cells
Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3687 - 3698.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Rajala, R. E. Anderson, J.-X. Ma, J. Lem, M. R. Al-Ubaidi, and R. V. S. Rajala
G-protein-coupled Receptor Rhodopsin Regulates the Phosphorylation of Retinal Insulin Receptor
J. Biol. Chem., March 30, 2007; 282(13): 9865 - 9873.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
X. Yi, M. Schubert, N. S. Peachey, K. Suzuma, D. J. Burks, J. A. Kushner, I. Suzuma, C. Cahill, C. L. Flint, M. A. Dow, et al.
Insulin Receptor Substrate 2 Is Essential for Maturation and Survival of Photoreceptor Cells
J. Neurosci., February 2, 2005; 25(5): 1240 - 1248.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Yu, R. V. S. Rajala, J. F. McGinnis, F. Li, R. E. Anderson, X. Yan, S. Li, R. V. Elias, R. R. Knapp, X. Zhou, et al.
Involvement of Insulin/Phosphoinositide 3-Kinase/Akt Signal Pathway in 17{beta}-Estradiol-mediated Neuroprotection
J. Biol. Chem., March 26, 2004; 279(13): 13086 - 13094.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. E. N. Reiter, L. Sandirasegarane, E. B. Wolpert, M. Klinger, I. A. Simpson, A. J. Barber, D. A. Antonetti, M. Kester, and T. W. Gardner
Characterization of insulin signaling in rat retina in vivo and ex vivo
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E763 - E774.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. V. S. Rajala, M. E. McClellan, J. D. Ash, and R. E. Anderson
In Vivo Regulation of Phosphoinositide 3-Kinase in Retina through Light-induced Tyrosine Phosphorylation of the Insulin Receptor beta -Subunit
J. Biol. Chem., November 1, 2002; 277(45): 43319 - 43326.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire